Trevena

TRVN NASDAQ
1.085
+0.025
+2.39%
交易中 15:11 06/17 EDT
开盘
1.060
昨收
1.060
最高
1.110
最低
1.060
成交量
34.92万
成交均量(3M)
129.40万
52周最高
3.578
52周最低
0.3823
换手率
0.38%
市值
1.00亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Trevena TRVN股票价格,Trevena股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
展开 >

最近浏览

名称
价格
涨跌幅